Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Nvidia stock rises after the artificial-intelligence chip maker unveils its next generation gaming graphic cards, while ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...

The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.

Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a ...

Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...

The company said Monday that fosigotifator failed to outperform placebo in slowing the neurogenerative disease, but is ...